Top

Published in:

01-06-2016 | Original Article

Resveratrol reduces IL-6 and VEGF secretion from co-cultured A549 lung cancer cells and adipose-derived mesenchymal stem cells

Authors: Erhan Sahin, Cengiz Baycu, Ayse Tansu Koparal, Dilek Burukoglu Donmez, Ezgi Bektur

Published in: Tumor Biology | Issue 6/2016

Abstract

Stem cell therapies are important treatment methodologies used in many areas of experimental or clinical medicine. In recent studies of cancer models, Mesenchymal stem cells (MSCs) suppressed the growth of cancer cells. However, also in some studies, stem cell treatments have been shown to induce cancer formation, increase tumor volume, induce the formation of new vessels, and lead to cancer invasion. The presence of MSC-secreted cytokines and their effects on cancer cells limits the reliability of MSC-based treatments. Resveratrol (trans-3,5,4′-trihydroxystilbene), an antioxidant found in red wine, has been shown to have therapeutic effects against several cancers. The aim of this study was to co-culture MSCs with A549 cancer cells to suppress the release of cancer-promoting cytokines from MSCs and to increase the applicability and reliability of stem cell therapies with resveratrol. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and neutral red cell viability assays were used to find safety dose of resveratrol. The MSCs secreted the cytokines IL-6 and VEGF, and the effect of resveratrol on these cytokines was analyzed by ELISA and western blot analysis of conditioned medium. One μM of resveratrol was found to be the safety dose for the A549 cancer cells and MSCs. We observed the highest release of IL-6 and VEGF from the co-cultured A549 cells and MSCs, and resveratrol was found to significantly decrease the release of these cytokines. Our study suggests that resveratrol exerts a positive effect on the release of cytokines. The safety dose of resveratrol can be administered together with stem cells during stem cell treatment.

Yao W, Hu Q, Ma Y, Xiong W, Wu T, Cao J et al. Human adipose-derived mesenchymal stem cells repair cisplatin-induced acute kidney injury through antiapoptotic pathways. Exp Ther Med. 2015.

Hou L, Wang X, Zhou Y, Ma H, Wang Z, He J, et al. Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells. Tumor Biol. 2014;35(2):1239–50.CrossRef

Bang OY. Autologous mesenchymal stem cell therapy in patients with stroke. Cell Therapy for Brain Injury. Springer; 2015. p. 21–35.

Wei X, Yang X. Han Z-p, Qu F-f, Shao L, Shi Y-f. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–54.CrossRefPubMedPubMedCentral

Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012;5(1):19.CrossRefPubMedPubMedCentral

Torsvik A, Bjerkvig R. Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev. 2013;39(2):180–8.CrossRefPubMed

Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011;71(2):614–24.CrossRefPubMedPubMedCentral

Saglam O, Unal ZS, Subasi C, Ulukaya E, Karaoz E. IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis. Tumour Biol J Int Soc Oncol Dev Biol Med. 2015;36(7):5667–77.CrossRef

Smith PC, Hobisch A, Lin D-L, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12(1):33–40.CrossRefPubMed

10.

George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, et al. Vegf-a, vegf-c, and vegf-d in colorectal cancer progression. Neoplasia. 2001;3(5):420–7.CrossRefPubMedPubMedCentral

11.

Galie M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene. 2008;27(18):2542–51.CrossRefPubMed

12.

Tao K, Bai X, Jia W, Liu Y, Zhu X, Han J, et al. Effects of resveratrol on the treatment of inflammatory response induced by severe burn. Inflammation. 2015;38(3):1273–80.CrossRefPubMed

13.

Tung BT, Rodríguez-Bies E, Talero E, Gamero-Estévez E, Motilva V, Navas P, et al. Anti-inflammatory effect of resveratrol in old mice liver. Exp Gerontol. 2015;64:1–7.CrossRefPubMed

14.

Yu XD, Yang JL, Zhang WL, Liu DX. Resveratrol inhibits oral squamous cell carcinoma through induction of apoptosis and G2/M phase cell cycle arrest. Tumour Biol J Int Soc Oncol Dev Biol Med. 2015.

15.

Yan H-W, Hu W-X, Zhang J-Y, Wang Y, Xia K, Peng M-Y, et al. Resveratrol induces human K562 cell apoptosis, erythroid differentiation, and autophagy. Tumor Biol. 2014;35(6):5381–8.CrossRef

16.

Peltz L, Gomez J, Marquez M, Alencastro F, Atashpanjeh N, Quang T, et al. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One. 2012;7(5):e37162.CrossRefPubMedPubMedCentral

17.

Zakaria N, Yusoff NM, Zakaria Z, Lim MN, Baharuddin PJN, Fakiruddin KS, et al. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer. 2015;15(1):84.CrossRefPubMedPubMedCentral

18.

Borenfreund E, Puerner JA. A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90). J Tissue Cult Methods. 1985;9(1):7–9.CrossRef

19.

Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014;84(1):13–22.CrossRefPubMed

20.

Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22.CrossRefPubMed

21.

Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells. 2010;2(1):5.CrossRefPubMedPubMedCentral

22.

Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211(1):27–35.CrossRefPubMed

23.

Scherzad A, Steber M, Gehrke T, Rak K, Froelich K, Schendzielorz P, et al. Human mesenchymal stem cells enhance cancer cell proliferation via IL-6 secretion and activation of ERK1/2. Int J Oncol. 2015;47(1):391–7.PubMed

24.

Agrawal M, Kumar V, Kashyap MP, Khanna VK, Randhawa GS, Pant AB. Ischemic insult induced apoptotic changes in PC12 cells: protection by trans resveratrol. Eur J Pharmacol. 2011;666(1):5–11.CrossRefPubMed

25.

Kumar V, Tripathi VK, Singh AK, Lohani M, Kuddus M. Trans-resveratrol restores the damages induced by organophosphate pesticide-monocrotophos in neuronal cells. Toxicol Int. 2013;20(1):48.CrossRefPubMedPubMedCentral

26.

Gu S, Chen C, Jiang X, Zhang Z. Resveratrol synergistically triggers apoptotic cell death with arsenic trioxide via oxidative stress in human lung adenocarcinoma A549 cells. Biol Trace Elem Res. 2015;163(1–2):112–23.CrossRefPubMed

27.

Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol. 2010;33(2):61–79.CrossRef

28.

Hsu H-S, Lin J-H, Hsu T-W, Su K, Wang C-W, Yang K-Y, et al. Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung Cancer. 2012;75(2):167–77.CrossRefPubMed

29.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK et al., editors. Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in cancer biology; 2015: Elsevier.

30.

Scherzed A, Hackenberg S, Radeloff A, Froelich K, Rak K, Hagen R, et al. Human mesenchymal stem cells promote cancer motility and cytokine secretion in vitro. Cells Tissues Organs. 2013;198(5):327–37.CrossRefPubMed

31.

Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 2015;6(2):715.CrossRefPubMed

32.

Chen D, Liu S, Ma H, Liang X, Ma H, Yan X, et al. Paracrine factors from adipose-mesenchymal stem cells enhance metastatic capacity through Wnt signaling pathway in a colon cancer cell co-culture model. Cancer Cell Int. 2015;15(1):42.CrossRefPubMedPubMedCentral

Title: Resveratrol reduces IL-6 and VEGF secretion from co-cultured A549 lung cancer cells and adipose-derived mesenchymal stem cells
Authors: Erhan Sahin
Cengiz Baycu
Ayse Tansu Koparal
Dilek Burukoglu Donmez
Ezgi Bektur
Publication date: 01-06-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4643-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer

Downregulation of SATB1 increases the invasiveness of Jurkat cell via activation of the WNT/β-catenin signaling pathway in vitro

Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response

A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice

Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer